RATIONALE: There is increasing evidence that emphysema is associated with primary loss of pulmonary capillary endothelium. Plasma levels of endothelial microparticles (EMPs), small vesicles released from activated or apoptotic endothelial cells, are elevated in vascular-related disorders. OBJECTIVES: To evaluate whether plasma EMP levels are elevated in smokers with early lung destruction as assessed by normal spirometry but reduced diffusing capacity of the lung for carbon monoxide (Dl(co)). METHODS: Lung health was assessed by pulmonary function tests (PFTs: spirometry, total lung capacity, Dl(co)) and chest X-ray; smoking status was assessed by urine nicotine and cotinine. EMP levels (CD42b(-)CD31(+) microparticles) were quantified as activated or apoptotic. The initial cohort (n = 92) included healthy nonsmokers (normal PFTs), healthy smokers (normal PFTs), and smokers with early evidence of lung destruction (normal spirometry, low Dl(co)). Two prospective cohorts were then tested: a group similar to the initial cohort and an HIV1(+) cohort. MEASUREMENTS AND MAIN RESULTS: Healthy smokers had mildly increased levels of EMPs. Strikingly, 95% of smokers with normal spirometry, low Dl(co) had increased EMPs, with reduced CD62(+)/CD31(+) ratios (P < 10(-4)) and elevated CD42b(-)CD31(+) annexin V(+) EMPs (P < 10(-4)), suggesting derivation from endothelial apoptosis. Most elevated EMPs were angiotensin-converting enzyme positive, suggesting derivation from pulmonary capillaries. Both prospective cohorts confirmed the initial cohort data. CONCLUSIONS: Plasma EMPs with apoptotic characteristics are elevated in smokers with normal spirometry but reduced Dl(co), consistent with the concept that emphysema is associated, in part, with capillary endothelium apoptosis, suggesting that the early development of emphysema might be monitored with plasma EMP levels.
RATIONALE: There is increasing evidence that emphysema is associated with primary loss of pulmonary capillary endothelium. Plasma levels of endothelial microparticles (EMPs), small vesicles released from activated or apoptotic endothelial cells, are elevated in vascular-related disorders. OBJECTIVES: To evaluate whether plasma EMP levels are elevated in smokers with early lung destruction as assessed by normal spirometry but reduced diffusing capacity of the lung for carbon monoxide (Dl(co)). METHODS: Lung health was assessed by pulmonary function tests (PFTs: spirometry, total lung capacity, Dl(co)) and chest X-ray; smoking status was assessed by urine nicotine and cotinine. EMP levels (CD42b(-)CD31(+) microparticles) were quantified as activated or apoptotic. The initial cohort (n = 92) included healthy nonsmokers (normal PFTs), healthy smokers (normal PFTs), and smokers with early evidence of lung destruction (normal spirometry, low Dl(co)). Two prospective cohorts were then tested: a group similar to the initial cohort and an HIV1(+) cohort. MEASUREMENTS AND MAIN RESULTS: Healthy smokers had mildly increased levels of EMPs. Strikingly, 95% of smokers with normal spirometry, low Dl(co) had increased EMPs, with reduced CD62(+)/CD31(+) ratios (P < 10(-4)) and elevated CD42b(-)CD31(+) annexin V(+) EMPs (P < 10(-4)), suggesting derivation from endothelial apoptosis. Most elevated EMPs were angiotensin-converting enzyme positive, suggesting derivation from pulmonary capillaries. Both prospective cohorts confirmed the initial cohort data. CONCLUSIONS: Plasma EMPs with apoptotic characteristics are elevated in smokers with normal spirometry but reduced Dl(co), consistent with the concept that emphysema is associated, in part, with capillary endothelium apoptosis, suggesting that the early development of emphysema might be monitored with plasma EMP levels.
Authors: Michael Harrison; Ronan P Murphy; Paul L O'Connor; Donal J O'Gorman; Noel McCaffrey; Philip M Cummins; Niall M Moyna Journal: Eur J Appl Physiol Date: 2009-04-05 Impact factor: 3.078
Authors: U Erdbruegger; M Grossheim; B Hertel; K Wyss; T Kirsch; A Woywodt; H Haller; M Haubitz Journal: Rheumatology (Oxford) Date: 2008-10-16 Impact factor: 7.580
Authors: Matthew R Lammi; Lesley Ann Saketkoo; Samuel C Okpechi; Mohamed A Ghonim; Dorota Wyczechowska; Natalie Bauer; Kusma Pyakurel; Saito Saito; Bennett P deBoisblanc; A Hamid Boulares Journal: Respirology Date: 2019-02-12 Impact factor: 6.424
Authors: Qiang Shi; Vida Hodara; Qinghe Meng; V Saroja Voruganti; Karen Rice; Joel E Michalek; Anthony G Comuzzie; John L VandeBerg Journal: Am J Cardiovasc Dis Date: 2014-10-11
Authors: Katja Hueper; Jens Vogel-Claussen; Megha A Parikh; John H M Austin; David A Bluemke; James Carr; Jiwoong Choi; Thomas A Goldstein; Antoinette S Gomes; Eric A Hoffman; Steven M Kawut; Joao Lima; Erin D Michos; Wendy S Post; Ming Jack Po; Martin R Prince; Kiang Liu; Dan Rabinowitz; Jan Skrok; Ben M Smith; Karol Watson; Youbing Yin; Alan M Zambeli-Ljepovic; R Graham Barr Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Jiajun Xu; Ming Yang; Paul Kosterin; Brian M Salzberg; Tatyana N Milovanova; Veena M Bhopale; Stephen R Thom Journal: Toxicol Appl Pharmacol Date: 2013-09-30 Impact factor: 4.219
Authors: Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar Journal: Am J Physiol Heart Circ Physiol Date: 2019-02-01 Impact factor: 4.733
Authors: Matthew R Gingo; Jiayan He; Catherine Wittman; Carl Fuhrman; Joseph K Leader; Cathy Kessinger; Lorrie Lucht; William A Slivka; Yingze Zhang; Deborah K McMahon; Frank C Sciurba; Alison Morris Journal: Eur Respir J Date: 2013-02-21 Impact factor: 16.671